RAPT Therapeutics, Inc. (NASDAQ:RAPT) Receives Average Recommendation of “Hold” from Analysts

Shares of RAPT Therapeutics, Inc. (NASDAQ:RAPT) have received an average rating of “Hold” from the nine brokerages that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating and two have issued a buy rating on the company. The average twelve-month price objective among brokerages that have issued a report on the stock in the last year is $5.29.

RAPT has been the subject of a number of recent analyst reports. Piper Sandler cut RAPT Therapeutics from an “overweight” rating to a “neutral” rating and dropped their price objective for the company from $8.00 to $2.00 in a report on Monday, November 11th. HC Wainwright upgraded RAPT Therapeutics from a “neutral” rating to a “buy” rating and set a $10.00 price objective for the company in a report on Thursday, December 26th. Wells Fargo & Company lowered their target price on RAPT Therapeutics from $17.00 to $4.00 and set an “overweight” rating for the company in a report on Tuesday, November 12th. JPMorgan Chase & Co. cut RAPT Therapeutics from a “neutral” rating to an “underweight” rating in a report on Monday, November 11th. Finally, Stifel Nicolaus reiterated a “hold” rating and issued a $2.00 target price (down from $7.00) on shares of RAPT Therapeutics in a report on Wednesday, November 13th.

Institutional Trading of RAPT Therapeutics

Hedge funds have recently modified their holdings of the stock. Picton Mahoney Asset Management lifted its position in shares of RAPT Therapeutics by 994.4% in the fourth quarter. Picton Mahoney Asset Management now owns 16,175 shares of the company’s stock valued at $26,000 after acquiring an additional 14,697 shares in the last quarter. JPMorgan Chase & Co. lifted its position in shares of RAPT Therapeutics by 298.2% in the third quarter. JPMorgan Chase & Co. now owns 16,703 shares of the company’s stock valued at $34,000 after acquiring an additional 25,130 shares in the last quarter. Readystate Asset Management LP acquired a new stake in shares of RAPT Therapeutics in the third quarter valued at approximately $36,000. Barclays PLC increased its holdings in shares of RAPT Therapeutics by 277.2% in the third quarter. Barclays PLC now owns 39,729 shares of the company’s stock valued at $79,000 after purchasing an additional 29,195 shares during the last quarter. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC acquired a new stake in shares of RAPT Therapeutics in the fourth quarter valued at approximately $63,000. Hedge funds and other institutional investors own 99.09% of the company’s stock.

RAPT Therapeutics Stock Down 0.8 %

RAPT opened at $1.25 on Friday. The business has a fifty day moving average of $1.28 and a 200 day moving average of $1.64. RAPT Therapeutics has a 52-week low of $0.79 and a 52-week high of $10.09. The stock has a market cap of $43.70 million, a P/E ratio of -0.45 and a beta of 0.03.

About RAPT Therapeutics

RAPT Therapeutics, Inc, a clinical-stage immunology-based biopharmaceutical company, focuses on discovery, development, and commercialization of oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases in the United States. The company's lead inflammation drug candidate is zelnecirnon (RPT193), a C-C motif chemokine receptor 4 (CCR4) antagonist that selectively inhibit the migration of type 2 T helper cells into inflamed tissues.